Cargando…

Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data

INTRODUCTION: Triptans, the most commonly prescribed acute treatments for migraine attacks are, per FDA labeling, contraindicated in cardiovascular (CV) disease patients and have warnings and precautions for those with CV risk factors. METHODS: Headache specialists, cardiologists, and health economi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dodick, David W., Shewale, Anand S., Lipton, Richard B., Baum, Seth J., Marcus, Steven C., Silberstein, Stephen D., Pavlovic, Jelena M., Bennett, Nathan L., Young, William B., Viswanathan, Hema N., Doshi, Jalpa A., Weintraub, Howard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585888/ https://www.ncbi.nlm.nih.gov/pubmed/33095099 http://dx.doi.org/10.1177/2150132720963680

Ejemplares similares

Acute treatment patterns in patients with migraine newly initiating a triptan
por: Lipton, Richard B, et al.
Publicado: (2020)

Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response
por: Marcus, Steven C, et al.
Publicado: (2020)

Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II
por: Dodick, David W., et al.
Publicado: (2020)

Evaluation of the 6‐item Identify Chronic Migraine screener in a large medical group
por: Pavlovic, Jelena M., et al.
Publicado: (2021)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary
por: Lipton, Richard B., et al.
Publicado: (2021)

Epidemiology, Demographics, Triptan Contraindications, and Prescription Patterns of Patients with Migraine: A German Claims Database Study
por: Gendolla, Astrid, et al.
Publicado: (2021)

Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials
por: Lipton, Richard B., et al.
Publicado: (2022)

The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
por: Silberstein, S, et al.
Publicado: (2013)

Migraine headache is present in the aura phase – a prospective study
por: Hansen, JM, et al.
Publicado: (2013)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
por: Aurora, SK, et al.
Publicado: (2014)

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
por: Silberstein, Stephen D, et al.
Publicado: (2015)

Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
por: Hepp, Zsolt, et al.
Publicado: (2016)

Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM)
por: Lipton, Richard B, et al.
Publicado: (2015)

EHMTI-0032. Persistence and switching characteristics among chronic migraine patient population: a retrospective claims analysis
por: Hepp, Z, et al.
Publicado: (2014)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

The migraine postdrome: An electronic diary study
por: Giffin, Nicola J., et al.
Publicado: (2016)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2023)

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

Burden of migraine related to menses: results from the AMPP study
por: Pavlović, Jelena M, et al.
Publicado: (2015)

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
por: Saper, Joel R, et al.
Publicado: (2011)

Use of a medication-based algorithm to identify advanced Parkinson's disease in administrative claims data: Associations with claims-based indicators of disease severity
por: Dahodwala, Nabila, et al.
Publicado: (2020)

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study
por: Schwedt, Todd J., et al.
Publicado: (2018)

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
por: Diener, Hans-Christoph, et al.
Publicado: (2019)

Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Analysis of Drug-Drug Interactions in Swiss Claims Data Using Tizanidine and Ciprofloxacin as a Prototypical Contraindicated Combination
por: Jödicke, Annika M., et al.
Publicado: (2018)

The impact of midlife on migraine in women: summary of current views
por: Pavlović, Jelena M.
Publicado: (2020)

Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial
por: Lipton, Richard B, et al.
Publicado: (2021)

Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
por: Lipton, Richard B., et al.
Publicado: (2021)

Psoriasis in the U.S. Medicare population: prevalence, treatment, and factors associated with biologic use
por: Takeshita, Junko, et al.
Publicado: (2015)

Associations between lifestyle intervention‐related changes in dietary targets and migraine headaches among women in the Women's Health and Migraine (WHAM) randomized controlled trial
por: Evans, Whitney E., et al.
Publicado: (2020)

Interrelationships of Sleep Quality, Obesity Severity, and Clinical Headache Features among Women with Comorbid Migraine and Obesity
por: Schumacher, Leah M., et al.
Publicado: (2023)

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
por: Kuca, Bernice, et al.
Publicado: (2018)

Migraine and risk of stroke
por: Øie, Lise R, et al.
Publicado: (2020)

Systematic review of outcomes and endpoints in preventive migraine clinical trials
por: McGinley, James S., et al.
Publicado: (2021)

Systematic review of outcomes and endpoints in acute migraine clinical trials
por: Houts, Carrie R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sq0h9t4eae1j4tqka4hgisucns